Cargando…

Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab

The autophagy involved in the occurrence, development and prognosis of human epidermal growth factor receptor 2 (HER2) gene-amplified cancer also controls the resistance of this type of cancer to the monoclonal antibody, trastuzumab (Tzb). In the present study, Tzb resistance was established in HER2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Hua, Chai, Xuyu, Wang, Xiaoyu, Zheng, Qi, Zheng, Dingcheng, Wu, Feng, Zheng, Cheng, Chen, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835962/ https://www.ncbi.nlm.nih.gov/pubmed/29541179 http://dx.doi.org/10.3892/ol.2018.7891

Ejemplares similares

Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab
por: Ma, Pengkai, et al.
Publicado: (2015)

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2009)

DRAM1 Regulates Autophagy Flux through Lysosomes
por: Zhang, Xing-Ding, et al.
Publicado: (2013)

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells
por: Wang, Chao, et al.
Publicado: (2021)

TFE3, a potential therapeutic target for Spinal Cord Injury via augmenting autophagy flux and alleviating ER stress
por: Zhou, Kailiang, et al.
Publicado: (2020)

Extravasation of an antibody‐drug conjugate: A case report of epidermal necrosis after trastuzumab‐emtansine extravasation
por: Sallevelt, Bastiaan T. G. M., et al.
Publicado: (2020)

Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer
por: Yu, Chaoran, et al.
Publicado: (2018)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy
por: Kadowaki, Shigenori, et al.
Publicado: (2014)

Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study
por: Deng, Ting, et al.
Publicado: (2023)

Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2
por: Wu, Jianhua, et al.
Publicado: (2021)

An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
por: Lu, Qiong, et al.
Publicado: (2016)

The impact of delayed gastric emptying as measured by gastric emptying scintigraphy on the outcome of magnetic sphincter augmentation
por: Eriksson, Sven E., et al.
Publicado: (2023)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
por: Zhang, Anli, et al.
Publicado: (2010)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
por: Wang, Chao, et al.
Publicado: (2017)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
por: Yang, Ju, et al.
Publicado: (2023)

Mitochondrial caspase keeps autophagy in flux
por: Short, Ben
Publicado: (2014)

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
por: Yamaguchi, Kensei, et al.
Publicado: (2023)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Ginsenoside Rg2 protects cardiomyocytes against trastuzumab-induced toxicity by inducing autophagy
por: Liu, Guang, et al.
Publicado: (2021)

Locoregional therapy with α‐emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2‐positive gastric cancer in mice
por: Li, Huizi Keiko, et al.
Publicado: (2017)

Prognostic factors in stage I gastric cancer: A retrospective analysis
por: Zheng, Dingcheng, et al.
Publicado: (2020)

Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models
por: Chen, Hao, et al.
Publicado: (2015)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Around-the-Clock Noise Induces AD-like Neuropathology by Disrupting Autophagy Flux Homeostasis
por: Zheng, Pengfang, et al.
Publicado: (2022)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
por: Tong, Gangling, et al.
Publicado: (2020)

Autophagy in Gastric Mucosa: The Dual Role and Potential Therapeutic Target
por: Lu, Sheng-Yu, et al.
Publicado: (2021)

Measurement of autophagy flux in the nervous system in vivo
por: Castillo, K, et al.
Publicado: (2013)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy
por: Huang, Ping, et al.
Publicado: (2016)

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
por: Huang, Jingcao, et al.
Publicado: (2013)

Penile Epidermal Cyst in a Patient With Augmentation Penoplasty
por: Jung, Jae Hung, et al.
Publicado: (2013)

Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer
por: Arigami, Takaaki, et al.
Publicado: (2022)

Impairment of APPL1/Myoferlin facilitates adipogenic differentiation of mesenchymal stem cells by blocking autophagy flux in osteoporosis
por: Zhang, Yunhui, et al.
Publicado: (2022)

Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection
por: Ye, Hua, et al.
Publicado: (2022)

The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
por: Shi, Jiaolong, et al.
Publicado: (2018)

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
por: Haslem, Derrick S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qc286fbvbq9cueepuf3i4dcr0i